oru.sePublikationer
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Changes of cerebrospinal fluid cytokine profile as a result of switching from first line MS-therapies to rituximab
Department of Pharmacology and Clinical Neuroscience, Umeå University, Umeå, Sweden.
Unit of Research, Education and Development, Region Jämtland Härjedalen, Östersund, Sweden.
Department of Pharmacology and Clinical Neuroscience, Umeå University, Umeå, Sweden.
Örebro University, School of Medical Sciences. Orebro University Hospital. Department of Neurology and Neurophysiology.
Show others and affiliations
2016 (English)In: Multiple Sclerosis Journal, ISSN 1352-4585, E-ISSN 1477-0970, Vol. 22, no Suppl. 3, 622-622 p.Article in journal (Refereed) Published
Abstract [en]

Background: New treatment strategies in multiple sclerosis provide insights not only in the clinical effects but also, by their differences in mechanisms of action, in the immunopathological mechanisms behind disease activity.

Objective: This study describes the change in cyto- and chemokine profile over a two-year period in a cohort of patients with clinically stable RRMS after treatment shift from ongoing first-line injectable disease modifying therapy (iDMT), e.g. interferon beta or glatirameracetat, to the anti-CD20 depleting agent rituximab and the differences compared with a cohort of healthy controls.

Method: CSF from 73 patients with clinically stable RRMS was analysed by an elektrochemiluminiscens-based ELISA for a panel of 22 cytokines before and one and two year after treatment shift to rituximab and compared with 55 healthy controls.

Results: During the first year of treatment it was a significant reduction (p< 0.005) in levels of IL-6, IL-8, IL-10, IL-12, IL-15, IP-10, MCP-1, MDC, TARC, sICAM, sVCAM and a significant elevation (p< 0,005) in levels of IL-7 and MIP-1b.

Compared to healthy controls it was a significantly higher (p< 0,005) level of IFN-gamma, IL-6, IL-8, IL-10, IL-12, IL-15, TNF, IP-10, MDC, MIP-1a, MIP-1b, TARC, SAA, sICAM and sVCAM in patients with RRMS before treatment shift. Levels of IL-5 and IL-7 were significantly lower. One year after treatment shift the levels of IFN-gamma, IL-6, IL-7, IL-15, MIP-1a and SAA did not differ significantly between patients with RRMS and healthy controls.

Conclusion: This study demonstrates significant changes in cyto- and chemokine profile in patients with RRMS after treatment shift from iDMT to rituximab and compared with healthy controls.

Place, publisher, year, edition, pages
Sage Publications, 2016. Vol. 22, no Suppl. 3, 622-622 p.
National Category
Neurology
Identifiers
URN: urn:nbn:se:oru:diva-56853ISI: 000383267202388OAI: oai:DiVA.org:oru-56853DiVA: diva2:1084973
Conference
32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, England, September 14-17, 2016
Note

Funding Agencies:

BiogenIdec  

Novartis  

Merck Serono  

Bayer Schering Pharma  

Sanofi-Genzyme  

Baxter Medical 

Available from: 2017-03-27 Created: 2017-03-27 Last updated: 2017-03-27Bibliographically approved

Open Access in DiVA

No full text

Search in DiVA

By author/editor
Gunnarsson, Martin
By organisation
School of Medical SciencesOrebro University Hospital
In the same journal
Multiple Sclerosis Journal
Neurology

Search outside of DiVA

GoogleGoogle Scholar

Total: 8 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf